OmniComm Systems To Provide eClinical Solutions For Phase I HIV Trials
OmniComm Systems has announced that a major West coast biopharmaceutical company has selected OmniComm to provide eClinical solutions for two of its phase I HIV studies. Both HIV
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).